Current insights into the role of miRNA-125 in cardiovascular disease: potential biological markers and therapeutic targets
- Authors: Alieva A.M.1, Teplova N.V.1, Reznik E.V.1, Baikova I.E.1, Akhmedova M.F.2, Butenko A.V.3, Balagova B.Z.4, Modestova A.V.1, Kotikova I.A.1, Valiev R.K.5, Nikitin I.G.1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University
- AKFA Medline Clinic
- Scientific-Clinical Center N 2 of the Russian Research Center for Surgery named after Academician B.V. Petrovsky
- National Medical Research Center for Psychiatry and Narcology named after V.P. Serbsky
- The Loginov Moscow Clinical Scientific Center
- Issue: Vol 29, No 4 (2023)
- Pages: 311-324
- Section: Reviews
- URL: https://journals.rcsi.science/0869-2106/article/view/133934
- DOI: https://doi.org/10.17816/medjrf112141
- ID: 133934
Cite item
Abstract
Recently, miRNAs are being used as diagnostic markers for various pathological conditions. This review analyzed the main studies devoted to the role of miRNA-125 in the development of cardiovascular diseases. Members of the miRNA-125 family are involved in cell differentiation, proliferation, and apoptosis by targeting mRNAs associated with these cellular processes. This miRNA can enhance or inhibit pathological processes such as oncogenesis, muscle abnormalities, neurological disorders, and others. Members of the miRNA-125 family also influence the development and function of immune cells and are involved in immunological defense. Research shows that the miRNA-125 family is associated with cardiac development. They also play an important role in pathophysiological conditions of the cardiovascular system. However, the same miRNA-125 family members play different roles in different pathological processes. For example, miRNA-125b overexpression in cardiomyocytes can inhibit their apoptosis and inflammatory response. However, miRNA-125b is also a regulator of cardiac fibrosis; its overexpression in cardiac fibroblasts can enhance their proliferation. Therefore, in pathological conditions, miRNA-125b excess aggravates myocardial fibrosis and remodeling, destroys the original morphological structure of the heart, disrupts neovascularization processes, and aggravates apoptosis of cardiomyocytes in the damaged area. Thus, to avoid adverse reactions, the optimal dose and timing of therapeutic intervention using members of the miRNA-125 family, their inhibitors, and mimetics must be carefully determined. An expanded and accurate understanding of miRNA-125 functions in gene regulatory networks associated with cardiovascular pathology will enable the development of novel and innovative therapeutic strategies.
Full Text
##article.viewOnOriginalSite##About the authors
Amina M. Alieva
N.I. Pirogov Russian National Research Medical University
Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN-code: 2749-6427
MD, cand. sci. (med.), associate professor
Russian Federation, 1 Ostrovityanova street, 117997 MoscowNatalia V. Teplova
N.I. Pirogov Russian National Research Medical University
Email: teplova.nv@yandex.ru
ORCID iD: 0000-0002-7181-4680
SPIN-code: 9056-1948
MD, dr. sci. (med.), professor
Russian Federation, 1 Ostrovityanova street, 117997 Moscow,Elena V. Reznik
N.I. Pirogov Russian National Research Medical University
Email: elenaresnik@gmail.com
ORCID iD: 0000-0001-7479-418X
SPIN-code: 3494-9080
ResearcherId: N-6856-2016
MD, dr. sci. (med.), professor
Russian Federation, 1 Ostrovityanova street, 117997 Moscow,Irina E. Baikova
N.I. Pirogov Russian National Research Medical University
Email: 1498553@mail.ru
ORCID iD: 0000-0003-0886-6290
SPIN-code: 3054-8884
MD, cand. sci. (med.), associate professor
Russian Federation, 1, Ostrovityanova st., Moscow, 117997Madina F. Akhmedova
AKFA Medline Clinic
Email: drmadina@yandex.ru
MD, cand. sci. (med.)
Uzbekistan, TashkentAlexey V. Butenko
Scientific-Clinical Center N 2 of the Russian Research Center for Surgery named after Academician B.V. Petrovsky
Email: callcenter@ckbran.ru
ORCID iD: 0000-0003-4390-9276
MD, dr. sci. (med.), professor
Russian Federation, MoscowBela Z. Balagova
National Medical Research Center for Psychiatry and Narcology named after V.P. Serbsky
Email: 3088919@mail.ru
ORCID iD: 0009-0009-4556-1534
intern
Russian Federation, MoscowAnna V. Modestova
N.I. Pirogov Russian National Research Medical University
Email: a.modestowa@yandex.ru
ORCID iD: 0000-0002-7980-5500
MD, cand. sci. (med.), associate professor
Russian Federation, 1 Ostrovityanova street, 117997 MoscowIrina A. Kotikova
N.I. Pirogov Russian National Research Medical University
Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
SPIN-code: 1423-7300
student
Russian Federation, 1 Ostrovityanova street, 117997 MoscowRamiz K. Valiev
The Loginov Moscow Clinical Scientific Center
Email: Radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
SPIN-code: 2855-2867
MD, cand. sci. (med.)
Russian Federation, MoscowIgor G. Nikitin
N.I. Pirogov Russian National Research Medical University
Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881
SPIN-code: 3595-1990
MD, dr. sci. (med.), professor
Russian Federation, 1 Ostrovityanova street, 117997 MoscowReferences
- Mensah G, Roth G, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019;74(20):2529–2532. doi: 10.1016/j.jacc.2019.10.009
- Alieva AM, Reznik EV, Hasanova ET, et al. Clinical value of blood biomarkers in patients with chronic heart failure. The Russian Archives of Internal Medicine. 2018;8(5):333–345. (In Russ). doi: 10.20514/2226-6704-2018-8-5-333-345
- Kozhevnikova MV, Belenkov YuN. Biomarkers in heart failure: current and future. Kardiologiia. 2021;61(5):4–16. (In Russ). doi: 10.18087/cardio.2021.5.n1530
- Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular disease. Consilium Medicum. 2020;22(5):83–86. (In Russ). doi: 10.26442/20751753.2020.5.200186
- Aliyeva AM, Baykova IE, Kislyakov VA, et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Terapevticheskii Arkhiv. 2019;91(9):145–149. (In Russ). doi: 10.26442/00403660.2019.09.000226
- Alieva AM, Pinchuk TV, Voronkova KV, et al. Neopterin is a biomarker of chronic heart failure (review of modern literature). Consilium Medicum. 2021;23(10):756–759. (In Russ). doi: 10.26442/20751753.2021.10.201113
- Song Z, Gao R, Yan B. Potential roles of microRNA-1 and microRNA-133 in cardiovascular disease. Rev Cardiovasc Med. 2020;21(1):57–64. doi: 10.31083/j.rcm.2020.01.577
- Kalayinia S, Arjmand F, Maleki M, et al. MicroRNAs: roles in cardiovascular development and disease. Cardiovasc Pathol. 2021;50:107296. doi: 10.1016/j.carpath.2020.107296
- Romakina VV, Zhirov IV, Nasonova SN, et al. MicroRNAs as biomarkers of cardiovascular diseases. Kardiologiia. 2018;58(1): 66–71. (In Russ). doi: 10.18087/cardio.2018.1.1008
- Alieva AM, Teplova NV, Kislyakov VA, et al. Biomarkers in cardiology: microRNA and heart failure. Therapy. 2022;8(1):60–70. (In Russ). doi: 10.18565/therapy.2022.1.60-70
- Wang Y, Tan J, Wang L, et al. MiR-125 family in cardiovascular and cerebrovascular diseases. Front Cell Dev Biol. 2021;9:799049. doi: 10.3389/fcell.2021.799049
- Kong AS, Lai KS, Lim SE, et al. MiRNA in ischemic heart disease and its potential as biomarkers: a comprehensive review. Int J Mol Sci. 2022;23(16):9001. doi: 10.3390/ijms23169001
- Vegter E, van der Meer P, de Windt LJ, et al. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18(5):457–468. doi: 10.1002/ejhf.495
- Rodriguez A, Griffiths-Jones S, Ashurst J, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10A):1902–1910. doi: 10.1101/gr.2722704
- Siasos G, Bletsa E, Stampouloglou PK, et al. MicroRNAs in cardiovascular disease. Hellenic J Cardiol. 2020;61(3):165–173. doi: 10.1016/j.hjc.2020.03.003
- Nader J, Metzinger L, Maitrias P, et al. Aortic valve calcification in the era of non-coding RNAs: the revolution to come in aortic stenosis management? Noncoding RNA Res. 2020;5(2):41–47. doi: 10.1016/j.ncrna.2020.02.005
- Bousquet M, Nguyen D, Chen C, et al. MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica. 2012;97(11):1713–1721. doi: 10.3324/haematol.2011.061515
- Wang J, Wang Z, Li G. MicroRNA-125 in immunity and cancer. Cancer Lett. 2019;454:134–145. doi: 10.1016/j.canlet.2019.04.015
- Li G, So AV, Sookram R, et al. Epigenetic silencing of miR-125b is required for normal B-cell development. Blood. 2018;131(17): 1920–1930. doi: 10.1182/blood-2018-01-824540
- Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16(5):279–294. doi: 10.1038/nri.2016.40
- Chen CY, Lee DD, Choong OK, et al. Cardiac-specific microRNA-125b deficiency induces perinatal death and cardiac hypertrophy. Sci Rep. 2021;11(1):2377. doi: 10.1038/s41598-021-81700-y
- Deng S, Zhang Y, Xu C, et al. MicroRNA-125b-2 overexpression represses ectodermal differentiation of mouse embryonic stem cells. Int J Mol Med. 2015;36(2):355–362. doi: 10.3892/ijmm.2015.2238
- Grodecka-Szwajkiewicz D, Ulanczyk Z, Zagrodnik E, et al. Differential secretion of angiopoietic factors and expression of microRNA in umbilical cord blood from healthy appropriate-for-gestational-age preterm and term newborns-in search of biomarkers of angiogenesis-related processes in preterm birth. Int J Mol Sci. 2020;21(4):1305. doi: 10.3390/ijms21041305
- Wong SS, Ritner C, Ramachandran S, et al. MiR-125b promotes early germ layer specification through Lin28/let-7d and preferential differentiation of mesoderm in human embryonic stem cells. PLoS One. 2012;7(4):e36121. doi: 10.1371/journal.pone.0036121
- Che P, Liu J, Shan Z, et al. MiR-125a-5p impairs endothelial cell angiogenesis in aging mice via RTEF-1 downregulation. Aging Cell. 2014;13(5):926–934. doi: 10.1111/acel.12252
- Cheng NL, Chen X, Kim J, et al. MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. Aging Cell. 2015;14(2): 200–208. doi: 10.1111/acel.12294
- Xu CR, Fang QJ. Inhibiting glucose metabolism by miR-34a and miR-125b protects against hyperglycemia-induced cardiomyocyte cell death. Arq Bras Cardiol. 2021;116(3):415–422. doi: 10.36660/abc.20190529
- Sergienko IV, Ansheles AA. Pathogenesis, diagnosis and treatment of atherosclerosis: practical aspects. Russian Cardiology Bulletin. 2021;16(1):64–72. (In Russ). doi: 10.17116/Cardiobulletin20211601164
- Maitrias P, Metzinger-Le Meuth V, Massy Z, et al. MicroRNA deregulation in symptomatic carotid plaque. J Vasc Surg. 2015;62(5):1245–1250. doi: 10.1016/j.jvs.2015.06.136
- Lu JB, Yao XX, Xiu JC, Hu YW. MicroRNA-125b-5p attenuates lipopolysaccharide-induced monocyte chemoattractant protein-1 production by targeting inhibiting LACTB in THP-1 macrophages. Arch Biochem Biophys. 2016;590:64–71. doi: 10.1016/j.abb.2015.11.007
- Zhaolin Z, Jiaojiao C, Peng W, et al. OxLDL induces vascular endothelial cell pyroptosis through miR-125a-5p/TET2 pathway. J Cell Physiol. 2019;234(5):7475–7491. doi: 10.1002/jcp.27509
- Wen P, Cao H, Fang L, et al. miR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smooth muscle cells in a high-phosphate environment. Exp Cell Res. 2014;322(2): 302–312. doi: 10.1016/j.yexcr.2014.01.025
- Cao C, Zhang H, Zhao L, et al. MiR-125b targets DNMT3b and mediates p53 DNA methylation involving in the vascular smooth muscle cells proliferation induced by homocysteine. Exp Cell Res. 2016;347(1):95–104. doi: 10.1016/j.yexcr.2016.07.007
- Wang X, Chen S, Gao Y, et al. MicroRNA-125b inhibits the proliferation of vascular smooth muscle cells induced by platelet-derived growth factor BB. Exp Ther Med. 2021;22(2):791. doi: 10.3892/etm.2021.10223
- Gareri C, Iaconetti C, Sorrentino S, et al. MiR-125a-5p modulates phenotypic switch of vascular smooth muscle cells by targeting ETS-1. J Mol Biol. 2017;429(12):1817–1828. doi: 10.1016/j.jmb.2017.05.008
- Zhou H, Lin S, Hu Y, et al. MiR-125a-5p and miR-7 inhibits the proliferation, migration and invasion of vascular smooth muscle cell by targeting EGFR. Mol Med Rep. 2021;24(4):708. doi: 10.3892/mmr.2021.12347
- Zheng X, Wu Z, Xu K, et al. Interfering histone deacetylase 4 inhibits the proliferation of vascular smooth muscle cells via regulating MEG3/miR-125a-5p/IRF1. Cell Adh Migr. 2019;13(1): 41–49. doi: 10.1080/19336918.2018.1506653
- Ye D, Lou GN, Li AC, et al. MicroRNA-125a-mediated regulation of the mevalonate signaling pathway contributes to high glucose-induced proliferation and migration of vascular smooth muscle cells. Mol Med Rep. 2020;22(1):165–174. doi: 10.3892/mmr.2020.11077
- Vigili de Kreutzenberg S, Giannella A, Ceolotto G, et al. A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease. Diabetologia. 2022;65(9):1555–1568. doi: 10.1007/s00125-022-05733-2
- Ding X, Ge P, Liu Z, et al. Interaction between microRNA expression and classical risk factors in the risk of coronary heart disease. Sci Rep. 2015;5:14925. doi: 10.1038/srep14925
- Jia K, Shi P, Han X, et al. Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol Med Rep. 2016;14(1):184–194. doi: 10.3892/mmr.2016.5246
- Bayoumi AS, Park KM, Wang Y, et al. A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. J Mol Cell Cardiol. 2018;114:72–82. doi: 10.1016/j.yjmcc.2017.11.003
- Xiaochuan B, Qianfeng J, Min X, Xiao L. RASSF1 promotes cardiomyocyte apoptosis after acute myocardial infarction and is regulated by miR-125b. J Cell Biochem. 2020;121(1):489–496. doi: 10.1002/jcb.29236
- Dufeys C, Daskalopoulos EP, Castanares-Zapatero D, et al. AMPKα1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Res Cardiol. 2021;116(1):10. doi: 10.1007/s00395-021-00846-y
- Bie ZD, Sun LY, Geng CL, et al. MiR-125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts. Cell Biol Int. 2016;40(11):1224–1234. doi: 10.1002/cbin.10677
- Sun LY, Zhao JC, Ge XM, et al. Circ_LAS1L regulates cardiac fibroblast activation, growth, and migration through miR-125b/SFRP5 pathway. Cell Biochem Funct. 2020;38(4):443–450. doi: 10.1002/cbf.3486
- Ke H, Zhang X, Cheng L, et al. Bioinformatic analysis to explore key genes associated with brain ischemia-reperfusion injury in rats. Int J Neurosci. 2019;129(10):945–954. doi: 10.1080/00207454.2019.1595615
- Wang X, Ha T, Zou J, et al. MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. Cardiovasc Res. 2014;102(3): 385–395. doi: 10.1093/cvr/cvu044
- Li L, Zhang M, Chen W, et al. LncRNA-HOTAIR inhibition aggravates oxidative stress-induced H9c2 cells injury through suppression of MMP2 by miR-125. Acta Biochim Biophys Sin (Shanghai). 2018;50(10):996–1006. doi: 10.1093/abbs/gmy102
- Luo C, Ling GX, Lei BF, et al. Circular RNA PVT1 silencing prevents ischemia-reperfusion injury in rat by targeting microRNA-125b and microRNA-200a. J Mol Cell Cardiol. 2021;159: 80–90. doi: 10.1016/j.yjmcc.2021.05.019
- Hu W, Chang G, Zhang M, et al. MicroRNA-125a-3p affects smooth muscle cell function in vascular stenosis. J Mol Cell Cardiol. 2019;136:85–94. doi: 10.1016/j.yjmcc.2019.08.014
- Chen F, Liu H, Wu J, et al. miR-125a suppresses TrxR1 expression and is involved in H2O2-induced oxidative stress in endothelial cells. J Immunol Res. 2018;2018:6140320. doi: 10.1155/2018/6140320
- Svensson D, Gidlöf O, Turczyńska KM, et al. Inhibition of microRNA-125a promotes human endothelial cell proliferation and viability through an antiapoptotic mechanism. J Vasc Res. 2014;51(3):239–245. doi: 10.1159/000365551
- Díaz I, Calderón-Sánchez E, Toro RD, et al. miR-125a, miR-139 and miR-324 contribute to Urocortin protection against myocardial ischemia-reperfusion injury. Sci Rep. 2017;7(1):8898. doi: 10.1038/s41598-017-09198-x
- Zhang B, Mao S, Liu X, et al. MiR-125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure. Mol Med. 2021;27(1):72. doi: 10.1186/s10020-021-00328-w
- Galluzzo A, Gallo S, Pardini B, et al. Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing. ESC Heart Fail. 2021;8(4):2907–2919. doi: 10.1002/ehf2.13371
- Liu H, Deng S, Han L, et al. Mesenchymal stem cells, exosomes and exosome-mimics as smart drug carriers for targeted cancer therapy. Colloids Surf B Biointerfaces. 2022;209(Pt 1):112163. doi: 10.1016/j.colsurfb.2021.112163
- Nazari-Shafti T, Neuber S, Duran A, et al. MiRNA profiles of extracellular vesicles secreted by mesenchymal stromal cells-can they predict potential off-target effects? Biomolecules. 2020;10(9):1353. doi: 10.3390/biom10091353
- Lin F, Zhang S, Liu X, Wu M. Mouse bone marrow derived mesenchymal stem cells-secreted exosomal microRNA-125b-5p suppresses atherosclerotic plaque formation via inhibiting Map4k4. Life Sci. 2021;274:119249. doi: 10.1016/j.lfs.2021.119249
- Xiao C, Wang K, Xu Y, et al. Transplanted mesenchymal stem cells reduce autophagic flux in infarcted hearts via the exosomal transfer of miR-125b. Circ Res. 2018;123(5):564–578. doi: 10.1161/circresaha.118.312758
- Huang CC, Chen DY, Wei HJ, et al. Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs. Biomaterials. 2013;34(37):9441–9450. doi: 10.1016/j.biomaterials.2013.09.010
- Zhu LP, Tian T, Wang JY, et al. Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics. 2018;8(22):6163–6177. doi: 10.7150/thno.28021
- Herrero D, Albericio G, Higuera M, et al. The vascular niche for adult cardiac progenitor cells. Antioxidants (Basel). 2022;11(5):882. doi: 10.3390/antiox11050882
- Li L, Wang Q, Yuan Z, et al. LncRNA-MALAT1 promotes CPC proliferation and migration in hypoxia by up-regulation of JMJD6 via sponging miR-125. Biochem Biophys Res Commun. 2018;499(3): 711–718. doi: 10.1016/j.bbrc.2018.03.216